CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis

[1]  B. Weinshenker,et al.  CCR5Δ32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis , 2005, Journal of Neuroimmunology.

[2]  M. Schwartz,et al.  Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases , 2005, Journal of the Neurological Sciences.

[3]  G. Salemi,et al.  Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity , 2005, Neurology.

[4]  Julian C. Knight,et al.  Regulatory polymorphisms underlying complex disease traits , 2005, Journal of Molecular Medicine.

[5]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[6]  D. Comings,et al.  RANTES: a genetic risk marker for multiple sclerosis , 2004, Multiple sclerosis.

[7]  C. Carlson,et al.  Mapping complex disease loci in whole-genome association studies , 2004, Nature.

[8]  I. Elovaara,et al.  Increase in CCR5 Δ32/Δ32 genotype in multiple sclerosis , 2004 .

[9]  D. Comings,et al.  Association of CCR5 Δ32 deletion with early death in multiple sclerosis , 2004, Genetics in Medicine.

[10]  S. Heggarty,et al.  Influence of C C R5 δ32 polymorphism on multiple sclerosis susceptibility and disease course , 2004, Multiple sclerosis.

[11]  A. Achiron,et al.  A mutated CCR5 gene may have favorable prognostic implications in MS , 2003, Neurology.

[12]  M. Sudomoina,et al.  The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4–positive Russians , 2002, Neurology.

[13]  J H Simon,et al.  Eight-year follow-up study of brain atrophy in patients with MS , 2002, Neurology.

[14]  M. Nishimura,et al.  A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. , 2002, American journal of respiratory and critical care medicine.

[15]  P. Sørensen,et al.  Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) , 2002, Multiple sclerosis.

[16]  D. Clayton,et al.  Multiple sclerosis in sibling pairs: an analysis of 250 families , 2001, Journal of neurology, neurosurgery, and psychiatry.

[17]  R. Ransohoff,et al.  CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. , 2001, The American journal of pathology.

[18]  F Barkhof,et al.  Optimizing the association between disability and biological markers in MS , 2001, Neurology.

[19]  F Barkhof,et al.  Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. , 2001, Brain : a journal of neurology.

[20]  J. Newcombe,et al.  Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue , 2000, Journal of Neuroimmunology.

[21]  R. Doerge,et al.  Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis. , 2000, The American journal of pathology.

[22]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[23]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[24]  U. Wahn,et al.  Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.

[25]  Finn Sellebjerg,et al.  CCR5 Δ32, matrix metalloproteinase-9 and disease activity in multiple sclerosis , 2000, Journal of Neuroimmunology.

[26]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[28]  M. Clanet,et al.  Familial factors influence disability in MS multiplex families , 1999, Neurology.

[29]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[30]  C. Kleeberger,et al.  CCR5 promoter polymorphism and HIV-1 disease progression , 1998, The Lancet.

[31]  D. Comings.  Why different rules are required for polygenic inheritance: lessons from studies of the DRD2 gene. , 1998, Alcohol.

[32]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[33]  J. Newcombe,et al.  Expression of monocyte chemoattractant protein-1 and other β-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions , 1998, Journal of Neuroimmunology.

[34]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[35]  Kuan-Teh Jeang,et al.  Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32* , 1997, The Journal of Biological Chemistry.

[36]  G. Stewart,et al.  The CCR5 deletion mutation fails to protect against multiple sclerosis. , 1997, Human immunology.

[37]  A J Thompson,et al.  A comparison of the pathology of primary and secondary progressive multiple sclerosis. , 1994, Brain : a journal of neurology.

[38]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[39]  D. Silberberg,et al.  New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.

[40]  J. Haines,et al.  CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis , 2000, Immunogenetics.